The Cannaisseur Group, Inc.

What they do

TCRG was established in December 2020 and acquired a 51% interest in Atlanta CBD Inc. on January 4, 2021; that interest is the Company's only asset and operation. Atlanta CBD, founded in October 2018 and family-owned, began as a CBD boutique, opened a retail hemp store in 2019, and sells hemp extracts and CBD products through the trade name Inno Medicinals in Atlanta, Georgia, and via its website innomedicinals.com. TCRG manages and operates Atlanta CBD's business day-to-day and states it has transitioned into a health and wellness company.

Revenue drivers

• CBD and hemp products retail — Atlanta CBD sells leading brands of hemp extracts and CBD products through its Inno Medicinals retail location in Atlanta, Georgia. It is the Company's sole operating business and the source of the 51% of net profits TCRG is entitled to under the acquisition agreement.
• Direct-to-consumer e-commerce — Atlanta CBD offers a majority of its products direct to consumers through its website, https://innomedicinals.com. The filing states products are sold only where legal, to end users eighteen years of age or older residing in states that allow the products.
• Planned health and wellness products — TCRG states it intends to sell health and wellness products, including CBD-related products, and focused wellness products and wellness technology. These are described as planned offerings, not current revenue sources.

Recent performance

Revenue was $88,145 in 2022, $53,130 in 2023, $700 in 2024 and $0 in 2025. Net losses were $80,147 in 2022, $128,025 in 2023, $1.3 million in 2024 and $1.8 million in 2025, with diluted EPS of $0 in 2022 and 2023 and negative $0.03 in 2024 and 2025. Quarterly revenue was $0 for each of the quarters ended 2025-09-30, 2025-12-31, 2026-03-31 and 2026-06-30. At 2026-06-30, total assets were $41, total liabilities were $362,735 and shareholder equity was negative $362,694, with cash and equivalents of $41. Operating cash flow was negative $23,935 in 2022, negative $126,074 in 2023, negative $110,627 in 2024 and negative $127,451 in 2025.

Strategy

TCRG says it has transitioned from the hemp business into a health and wellness company and plans to provide sustainable health and wellness options, including focused wellness products and wellness technology. It intends to build on its business by acquiring CBD cultivation, processing and distribution equipment and infrastructure from companies that grow and develop CBD and other health-related consumer products. Such assets would be used to grow TCRG's business and support Atlanta CBD's operations. The Company states it plans to fund these acquisitions with a combination of equity (common stock) and funds raised from private placements.

Risks

• No revenue and going-concern financial condition — Revenue fell from $88,145 in 2022 to $0 in 2025 and has been $0 in each of the last four reported quarters, with negative shareholder equity of $362,694 and cash of $41 at 2026-06-30.
• Reliance on a single 51%-owned subsidiary — The Company's only asset and operation is its 51% interest in Atlanta CBD Inc.; it does not control the remaining 49%, which is owned by Floretta Gogo and Xavier Carter.
• Related-party concentration and potential conflicts — Ms. Gogo and Mr. Carter are TCRG's CEO and CFO, respectively, each own approximately 18% of TCRG, own the remaining 49% of Atlanta CBD, and run day-to-day operations of both entities; the filing states they have signed conflict-of-interest agreements.
• Regulatory limits on CBD product sales — The filing states products are sold only where legal and to end users eighteen years of age or older residing in states that allow the products, so the addressable market depends on state-level rules.

Outlook

The Company states it plans to expand into the health and wellness market and to acquire CBD cultivation, processing and distribution equipment and infrastructure. It intends to fund growth through a combination of common stock and private placements, and to work with Atlanta CBD to grow operations. No forward revenue or earnings guidance is provided in the excerpts.